Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
Therefore, this study warrants further dosimetric and clinical studies to determine the immunomodulatory effect and therapeutic efficacy of <sup>177</sup>Lu-iPD-L1 in treating PD-L1-positive tumors in combination with anti-PD-1/PD-L1 immunotherapy protocols.
Authors
- Guillermina Ferro‐Flores (ORCID: https://orcid.org/0000-0003-0296-7605)
- Pedro Cruz-Nova (ORCID: https://orcid.org/0000-0001-5719-7324)
- Rigoberto Oros‐Pantoja (ORCID: https://orcid.org/0000-0001-5441-0863)
- Myrna Luna‐Gutiérrez (ORCID: https://orcid.org/0000-0002-4082-3816)
- Clara Santos‐Cuevas (ORCID: https://orcid.org/0000-0001-5903-1598)
- Blanca Ocampo‐García (ORCID: https://orcid.org/0000-0002-5831-8412)
- Gerardo Bravo-Villegas (ORCID: https://orcid.org/0000-0003-4670-2908)
- Nallely Jiménez‐Mancilla (ORCID: https://orcid.org/0000-0001-9480-4621)
- Laura Meléndez‐Alafort (ORCID: https://orcid.org/0000-0003-0701-3616)
- Erika Azorín‐Vega (ORCID: https://orcid.org/0000-0002-7520-461X)
Institutions
- Universidad Autónoma del Estado de México (MX)
- Instituto Nacional de Investigaciones Nucleares (MX)
- Istituto Oncologico Veneto (IT)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s41181-025-00328-9
- Citations
- 8
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 11.77
Funders
- Ministero della Salute
- International Atomic Energy Agency
- Consejo Mexiquense de Ciencia y Tecnología